Industry Perspectives

The partnership leverages real-world patient data and advanced analytics to support faster, more patient-centered drug discovery.

A collaboration designed to overcome the limitations of cold-chain logistics by enabling safe, viable, and ready-to-use transport of microbiome-sensitive 3D skin constructs to customers worldwide.

The new investment accelerates development of a potential breakthrough therapy targeting the one-carbon metabolic pathway.

Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s research

Well-calibrated metrics reveal that AI virtual cells can reliably identify biologically significant signals and accelerate target discovery pipelines.

The acquisition brings together two leaders in scientific software to provide end-to-end support from molecular design and analytical characterization to manufacturing quality control.

A collaborative effort to co-develop scalable and reproducible sample preparation workflows for proteomics

Paired with OGT’s Interpret platform, the solution allows labs to visualise MRD dynamics over time and streamline workflows while maintaining accuracy and reproducibility.

Award-winner Cheng Lyu shows how tiny changes in circuit wiring can shift an animal’s behavior, illuminating the developmental rules of the nervous system.

Qureight’s Vascul8 model uses AI to analyse CT scans and identify patients at risk of residual pulmonary hypertension after surgery.

Lonza strengthens its pharmaceutical quality control portfolio through the acquisition of Redberry, enabling faster and more reliable microbial testing.

Ongoing collaboration aims to bring new treatments for neurodegenerative conditions closer to patients.